Revenue → Gross profit: $17.318BPharmaceutical → Revenue: $13.731BRevenue → Cost of revenue: $8.212BMedical devices → Revenue: $7.788BGross profit → Operating profit: $6.679BGross profit → SG&A: $6.665BOperating profit → Net profit: $5.144BImmunology → Pharmaceutical: $4.497BOncology → Pharmaceutical: $4.398BConsumer health → Revenue: $4.011BGross profit → R&D: $3.829BSurgery → Medical devices: $2.595BOrthopaedics → Medical devices: $2.265BNeuroscience → Pharmaceutical: $1.793BInterventional → Medical devices: $1.620BOperating profit → Tax: $1.618BVision → Medical devices: $1.308BInfectious diseases → Pharmaceutical: $1.121BPulmonary → Pharmaceutical: $0.972BOther pharma → Pharmaceutical: $0.950BGross profit → Restructuring: $0.145BOther → Operating profit: $0.060BInterest → Operating profit: $0.023BConsumer health: $4.011BRevenue: $25.530BImmunology: $4.497BPharmaceutical: $13.731BInfectious diseases: $1.121BNeuroscience: $1.793BOncology: $4.398BPulmonary: $0.972BOther pharma: $0.950BMedical devices: $7.788BInterventional: $1.620BOrthopaedics: $2.265BSurgery: $2.595BVision: $1.308BGross profit: $17.318BCost of revenue: $8.212BOperating profit: $6.762BSG&A: $6.665BR&D: $3.829BRestructuring: $0.145BNet profit: $5.144BInterest: $0.023BOther: $0.060BTax: $1.618Bcreated with SankeyArt.comConsumer health$4.011B5% Y/YRevenue$25.530B6% Y/YImmunology$4.497B2% Y/YPharmaceutical$13.731B3% Y/YInfectious diseases$1.121BNeuroscience$1.793BOncology$4.398BPulmonary$0.972BOther pharma$0.950BMedical devices$7.788B13% Y/YInterventional$1.620BOrthopaedics$2.265BSurgery$2.595BVision$1.308BGross profit$17.318B8% Y/YCost of revenue$8.212B4% Y/YOperating profit$6.762B15% Y/YSG&A$6.665B7% Y/YR&D$3.829B3% Y/YRestructuring$0.145BNet profit$5.144B7% Y/YInterest$23M-12% Y/YOther$60MTax$1.618B58% Y/YJohnson & Johnson Q2 FY23 Income Statement
2022
Q4 Full Year
2023
Q1 Q2 Q3 Q4 Full Year
2024
Q1 Q2 Q3